Unaudited Condensed Interim Financial Statements
For the Three and Six Months Ended April 30, 2025 and 2024
(Expressed in Canadian dollars)

NOTICE OF NO AUDITOR REVIEW OF INTERIM FINANCIAL STATEMENTS

The accompanying unaudited condensed interim financial statements of Cassius Ventures Ltd. ("the Company") have been prepared by and are the responsibility of the Company's management.

The Company's independent auditor has not performed a review of these condensed interim financial statements in accordance with the standards established by the Chartered Professional Accountants of Canada for a review of interim financial statements by an entity's auditor.

Condensed Interim Statements of Financial Position (Unaudited) (Expressed in Canadian Dollars)

		As at		As at
		April 30		October 31
		2025		2024
Assets				
Current assets				
Cash	\$	2,020	\$	2,887
Amounts receivable		708		-
TOTAL ASSETS	\$	2,728	\$	2,887
Liabilities Current liabilities				
Accounts payable and accrued liabilities (Note 3)	\$	179,704	\$	167,506
Due to related parties (Note 6)	Ť	25,812	Ψ	25,812
Promissory notes payable (Note 3)		295,000		282,000
TOTAL LIABILITIES		500,516		475,318
Shareholders' deficit				
Share capital		5,968,027		5,968,027
Contributed surplus (Note 5)		338,887		338,887
Deficit		(6,804,702)		(6,779,345)
Total shareholders' deficit		(497,788)		(472,431)
TOTAL LIABILITIES AND SHAREHOLDERS' DEFICIT	\$	2,728	\$	2,887

Nature of Operations and Continuance of Business (Note 1)

Approved for Issuance by the Board of Directors:	
"Gerrie van der Westhuizen"	Director
"Jason Birmingham"	Director

Condensed Interim Statements of Loss and Comprehensive Loss (Unaudited) For the Three and Six months ended April 30, 2025 and 2024 (Expressed in Canadian Dollars)

	Thre	e months ended	ТІ	hree months ended	Six Months ended	Six Months ended
		April 30		April 30	April 30	April 30
		2025		2024	2025	2024
Operating expenses						
Office and general	\$	173	\$	166	\$ 339	\$ 340
Professional fees		2,375		2,125	5,648	6,922
Share-based payments (Note 5 and 6)		-		1,734		5,694
Transfer agent and regulatory		4,569		2,164	9,363	6,180
Net loss from operations		(7,117)		(6,189)	(15,350)	(19,136)
Other expense						
Interest expense (Note 3)		(5,029)		(4,608)	(10,007)	(9,161)
Net loss and comprehensive loss	\$	(12,146)	\$	(10,797)	\$ (25,357)	\$ (28,297)
Loss per common share						
Basic and diluted	\$	(0.00)	\$	(0.00)	\$ (0.00)	\$ (0.00)
Weighted average number of common shares						
outstanding						
Basic and diluted		10,217,248		10,217,248	10,217,248	10,217,248

Condensed Interim Statements of Changes in Equity (Unaudited) For the Three and Six months ended April 30, 2025 and 2024 (Expressed in Canadian Dollars)

	Share	cap	oital			
	Number of shares	•	Amount	Contributed surplus	Deficit	Total Shareholders' Deficit
Balance - October 31, 2024	10,217,248	\$	5,968,027	\$ 338,887	\$ (6,779,345)	\$ (472,431)
Net loss for the period	-				(25,357)	(25,357)
Balance - April 30, 2025	10,217,248	\$	5,968,027	\$ 338,887	\$ (6,804,702)	\$ (497,788)
	Share	cap	oital			
	Number of shares		Amount	Contributed surplus	Deficit	Total Shareholders' Deficit
Balance - October 31, 2023	10,217,248	\$	5,968,027	\$ 332,650	\$ (6,727,653)	\$ (426,976)
Share-based payments Net loss for the period	<u>-</u>		-	5,694 -	- (28,297)	5,694 (28,297)
Balance - April 30, 2024	10,217,248	\$	5,968,027	\$ 338,344	\$ (6,755,950)	\$ (449,579)

Condensed Interim Statements of Cash Flows (Unaudited) For the Three and Six months ended April 30, 2025 and 2024 (Expressed in Canadian Dollars)

		months ended April 30, 2025	Th	nree months ended April 30, 2024		Six Months ended April 30, 2025		Six Months ended April 30, 2024
Operating activities								
Net loss for the period	\$	(12,146)	\$	(10,797)	\$	(25,357)	\$	(28,297)
Items not involving cash:	*	(,,-	Ψ.	(10,101)	*	(=0,00.7	Ψ.	(20,201)
Share-based payments		-		1,734		-		5,694
Net changes in non-cash working capital balances:								
Amounts receivable		(397)		(571)		(708)		(1,049)
Accounts payable and accrued liabilities		`597		5,869		12,198		10,762
Net cash used in operating activities		(11,946)		(3,765)		(13,867)		(12,890)
Financing activities								
Proceeds from promissory notes		6,500		-		13,000		15,000
Net cash provided by financing activities		6,500		-		13,000		15,000
Change in cash		(5,446)		(3,765)		(867)		2,110
Cash, beginning of the period		7,466		6,290		2,887		415
Cash, end of the period	\$	2.020	\$	2.525	\$	2.020	\$	2.525

Notes to the Condensed Interim Financial Statements For the Three and Six Months Ended April 30, 2025 and 2024 (Expressed in Canadian Dollars)

1. Nature of Operations and Continuance of Business

Cassius Ventures Ltd. (the "Company") is an exploration stage company focused on acquiring exploration and/or development stage mineral properties for the purposes of further exploration and development. The Company was incorporated under the Business Corporations Act (British Columbia) on February 23, 2007. The Company maintains its head office at 595 Burrard Street, Suite 3083, Vancouver, British Columbia. The Company's registered and records office is located at 733 Seymour Street, Suite 2900, Vancouver, British Columbia. Its common shares are traded on the NEX Board of the TSX Venture exchange under the symbol "CZ.H".

These financial statements have been prepared on a going concern basis, which assumes that the Company will continue in operation for the foreseeable future and will be able to realize its assets and discharge its liabilities in the normal course of business.

The Company has yet to generate any revenues from operations and as at April 30, 2025, had an accumulated deficit of \$6,804,702 and a working capital deficit of \$497,788. The above conditions, along with other factors indicate the existence of material uncertainties that may cast significant doubt upon the Company's ability to continue as a going concern. The Company's ability to continue operations in the normal course of business is dependent on several factors, including the ability to secure additional financing.

Although management is of the opinion that sufficient working capital will be obtained from a source of financing to meet the Company's remaining current liabilities as well as future liabilities and commitments as they become due, there is a risk that additional financing will not be available on a timely basis or on terms acceptable to the Company. The financial statements do not include any additional adjustments to the recoverability and classification of certain recorded asset amounts, and changes to the statement of loss and comprehensive loss that might be necessary if the Company was unable to continue as a going concern.

2. Basis of Presentation

These condensed interim financial statements have been prepared in accordance with International Financial Reporting Standards ("IFRS") applicable to the preparation of interim financial statements, including International Auditing Standard 34, Interim Financial Reporting ("IAS 34") as issued by the International Accounting Standards Board. These condensed interim financial statements do not include all disclosures required for annual audited financial statements. Accordingly, they should be read in conjunction with the notes to the Company's audited annual financial statements for the year ended October 31, 2024. The accounting policies followed in these condensed interim financial statements are the same as those applied in note 3 of the Company's audited annual financial statements for the year ended October 31, 2024.

The Board of Directors approved these financial statements on June 26, 2025.

3. Promissory Notes Payable

As at April 30, 2025, the Company had outstanding promissory notes totalling \$295,000 (October 31, 2024 - \$282,000). The promissory notes bear interest at 7% per annum, are unsecured, and payable on demand.

Interest expense incurred on the promissory notes for the three and six months ended April 30, 2025 totalled \$5,029 and \$10,007 (2024 - \$4,553 and \$9,161, respectively), which is included as part of Accounts Payable and Accrued Liabilities.

Notes to the Condensed Interim Financial Statements For the Three and Six Months Ended April 30, 2025 and 2024 (Expressed in Canadian Dollars)

4. Share Capital

The Company has an unlimited number of common shares without par value authorized.

5. Stock Options

The Company has established a stock option plan (the "Plan") for its directors, executive officers, employees and consultants under which the Company may grant options to acquire a maximum number of common shares equal to 10% of the total issued and outstanding common shares of the Company exercisable for a period of up to 5 years from the date of grant.

Within any 12-month period, the maximum number of common shares reserved for issuance to any individual cannot exceed 5% of the issued common shares, and the maximum number of common shares reserved for issuance to any insider cannot exceed 10% of the issued common shares. The aggregate number of common shares reserved for issuance to insiders cannot exceed 10% of the issued common shares. Within any 12-month period, the maximum number of options granted to any one consultant cannot exceed 2% of the issued common shares and the maximum number of options granted to all employees and consultants conducting investor relations activities cannot exceed 2% of the issued common shares.

The exercise price of an option granted under this plan shall not be less than the discounted market price provided that:

- (i) if options are granted within 90 days of a distribution by a prospectus, the minimum exercise price of those options will be the greater of the discounted market price and the per share price paid by the public investors for shares acquired under the distribution;
- (ii) the 90-day period begins on the date a final receipt is issued for the prospectus;
- (iii) for unit offerings, the minimum option exercise price will be the 'base' (or imputed) price of the shares included in the unit; and
- (iv) for all other financings, the minimum exercise price will be the average price paid by the public investors.

The options granted to an optionee under this Plan shall vest at the discretion of the Board. In accordance with the policies of the TSXV, and subject to their approval to the contrary, options issued to consultants providing investor relations services must vest (and not otherwise be exercisable) in stages over a minimum of 12 months with no more than 25% of the options vesting in any three-month period.

Total share-based payments recognized during the three and month period ended April 30, 2025 was \$Nil (2024 - \$1,734 and \$5,694, respectively) which was recorded within share-based payment expense in the statement of loss and comprehensive loss.

As at April 30, 2025, and October 31, 2024, the Company had the following stock options outstanding and exercisable:

	Number of options	We	ighted average exercise price
Options outstanding and exercisable - October 31, 2024	800,000	\$	0.06
Expired	-	\$	-
Granted	-	\$	
Options outstanding and exercisable - April 30, 2025	800,000	\$	0.06

As at April 30, 2025, the Company had 800,000 outstanding stock options with a weighted exercise price of \$0.06 and a weighted average remaining contractual life of 2.96 years.

Notes to the Condensed Interim Financial Statements For the Three and Six Months Ended April 30, 2025 and 2024 (Expressed in Canadian Dollars)

6. Related Party Transactions

a) Key Management Compensation

Key management for the three and six months ended April 30, 2025 include the Company's directors, Chief Executive Officer and Chief Financial Officer. During the three and six months ended April 30, 2025, the Company incurred \$Nil (2024 - \$1,734 and \$5,694, respectively) in share-based payments to key management personnel.

b) Payments for services by related parties

As of April 30, 2025, the Company owed \$25,812 (2024 - \$25,812) to a company with an officer in common. The amounts due are non-interest bearing, unsecured, and due on demand.

7. Fair Value of Financial Instruments

Fair value is based on available public market information or, when such information is not available, estimated using present value techniques and assumptions concerning the amount and timing of future cash flows and discount rates which factor in the appropriate credit risk. The carrying values of cash and cash equivalents, receivables, accounts payable, promissory notes, and due to related parties approximate their fair values due to their short-term nature.